6月24日，康方生物盘中上涨3.1%，报88.25港元，成交额2.42亿港元。消息面上，中信建投与兴业证券近日密集发布研报，分别给予"买入"及"增持"评级，叠加生物科技板块集体走强共同推动股价反弹。
中信建投认为公司凭借Tetrabody双抗技术平台确立"IO 2.0+ADC"双重战略方向，创新药产品市场空间广阔；兴业证券指出依沃西HARMONi-6 OS数据具里程碑意义，预计其2033年前有望实现150亿美元以上收入。此外，公司董事会此前批准最多2亿港元回购计划及管理层拟增持不超过5000万港元，产业资本护盘信号明确。同板块中科伦博泰生物涨6.88%、荣昌生物涨4.11%、百济神州涨3.6%，行业整体回暖。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.